Epoetin alfa for dialysis outpatients: Analysis of administered versus medicare-reimbursed units

Hospital Pharmacy

Volumn 34, Issue 11, 1999, Pages 1318-1321

  Oinonen, Michael J ^a   Chen, Connie ^a   Danekas, Lynne H ^a   Matuszewski, Karl A ^a   Vlasses, Peter H ^a  

^a University HealthSystem Consortium ^*  (United States)

Author keywords

Dialysis; Epoetin alfa; Erythropoietin; Health Care Finance Administration (HCFA); Medicare; Reimbursement

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; DRUG COST; HEALTH CARE FINANCING; HEMODIALYSIS; HUMAN; MEDICARE; OUTPATIENT; REIMBURSEMENT; REVIEW;

EID: 0033502594     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857879903401111     Document Type: Review

References (5)

1. Dwore RB, Murray BP, Parsons RJ, et al. Revenue enhancement through total quality management/continuous quality improvement (TQM/CQI) in outpatient coding and billing. J Hosp Mark. 1995; 9(2):63-93.
2. Malm P. Preventing revenue loss by complying with Medicare regulations. Caring. 1998;17(8):30-32.
3. Plunkett C. CPT (current procedure terminology) coding and patient accounting: Controlling the process and improving billing efficiency. Patient Acc. 1993;16(5): 2-3.
4. Koene RAP, Frenken LAM. Starting r-HuEpo in chronic renal failure: When, why, and how? Nephrol Dial Trans. 1995; 10:35-42.
5. Health Care Finance Administration. www.hcfa.gov/transmit/r5ch34p2.htm Accessed June 18, 1999.